Stock AnalizCVS HEALTH Corp CVS
Retail-Drug Stores and Proprietary Stores · data as of November 13, 2026
CVS HEALTH Corp (CVS) is a consumer staples company listed in the US with a market value of about $114.3B. In the twelve months to September 30, 2026 it had revenue of $420.6B and net income of $11.0B, a net margin of 2.6%.
Its overall Stock Analiz score is 2.4 out of 5 (weak). The strongest part is shareholder returns (5/5); the weakest is future growth (0/5).
Key numbers: a P/E of 10.4, a price to free cash flow of 7.3, 5-year revenue growth of 8% a year, a 5-year average ROIC of 5%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 60% above the current price.
Score: 2.4 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- 5-year revenue growth above 8% a year
- Profitable 5 years in a row
- Positive free cash flow
- Pays a dividend
Checks not passed
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $420.6B | $402.1B | $372.8B | $357.8B | $322.5B | $292.1B | $268.7B | $256.8B | $194.6B | $184.8B | $177.5B |
| Net income | $11.0B | $1.8B | $4.6B | $8.3B | $4.3B | $8.0B | $7.2B | $6.6B | -$594M | $6.6B | $5.3B |
| Free cash flow | $15.6B | $7.8B | $6.3B | $10.4B | $13.4B | $15.7B | $13.4B | $10.4B | $6.8B | $6.1B | $7.9B |
| EPS (diluted) | $8.61 | $1.39 | $3.66 | $6.47 | $3.26 | $6.02 | $5.46 | $5.08 | $-0.57 | $6.44 | $4.90 |
| Net margin | 2.6% | 0.4% | 1.2% | 2.3% | 1.3% | 2.7% | 2.7% | 2.6% | -0.3% | 3.6% | 3.0% |
| ROIC | — | 2.4% | 4.1% | 6.7% | 4.2% | 6.7% | 6.6% | 5.8% | 2.4% | 11.8% | 10.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 25 analysts is $110.32, 23% above the current price; targets range from $86.00 to $146.00; the consensus rating is “Strong buy”; expected EPS is $8.27 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is CVS HEALTH’s P/E ratio?
About 10.4, based on the last twelve months of diluted earnings per share (forward P/E about 10.9).
Is CVS HEALTH stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 60% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does CVS HEALTH pay a dividend?
Yes. The dividend yield is about 2.97%, and it has paid dividends for 10 years in our data.
Is CVS HEALTH a good stock to buy?
We do not give buy or sell advice. CVS HEALTH scores 2.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.